SDMHF News and Press, Sartorius Stedim Biotech From 07/29/21

Sartorius Stedim Biotech acquires cell culture specialist Xell AG - Extension of the Sartorius Stedim Biotech cell culture media business with a focus on media for gene therapeutics and vaccines - Significant expansion of capacities for manufacturing dry powder and liquid me...

The following slide deck was published by Sartorius Stedim Biotech S.A. in conjunction with their 2021 Q1 earnings call. For further details see: Sartorius Stedim Biotech S.A. 2021 Q1 - Results - Earnings Call Presentation

Sartorius Stedim Biotech S.A. (SDMHF) Q2 2021 Earnings Conference Call July 21, 2021, 09:30 AM ET Company Participants Joachim Kreuzburg - CEO Rainer Lehmann - CFO, Member of Executive Board Conference Call Participants Patrick Wood - Bank of America Michael Leuchten - UBS Paul Knight - KeyBa...

Sartorius Stedim Biotech S.A. (SDMHF): H1 GAAP EPS of €3.49.Revenue of €1.35B (+55.% Y/Y)Press Release For further details see: Sartorius Stedim Biotech S.A. reports H1 results

Half-year results of Sartorius Stedim Biotech - Sales revenue up 61.1 percent to 1,352 million euros; underlying EBITDA margin 36.1 percent - Dynamic organic growth; added momentum from pandemic-related business and acquisitions - Forecast for 2021 raised yet again at th...

Sartorius Stedim Biotech provides preliminary first-half financial key figures and raises forecast for 2021 Sartorius Stedim Biotech announces today that it expects strong first-half performance and raises its forecast for the full year of 2021. Disclosure of inside informat...

Sartorius Stedim Biotech strengthens product portfolio for cell and gene therapies by acquiring a majority stake in CellGenix - Portfolio expanded by cell culture components, such as growth factors, cytokines, and media - CellGenix site in Freiburg to be expanded into a cent...

First-quarter results of Sartorius Stedim Biotech PR Newswire AUBAGNE, France , April 21, 2021 /PRNewswire/ -- Sales revenue up 61.1 percent to 655 million euros; underlying EBITDA margin 35.4 percent A good 23 ...

On the basis of strong order intake during the first 10 weeks of 2021, Sartorius Stedim Biotech (SDMHF) has raised its growth forecast for FY2021.Management now projects consolidated sales growth of around 38% vs. prior outlook of 20%-26% and an underlying EBITDA margin of ~33% vs. previ...

Sartorius Stedim Biotech increases its full-year 2021 guidance PR Newswire AUBAGNE, France , March 18, 2021 /PRNewswire/ -- Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year,...